Adrian Woolfson

1.4k total citations
40 papers, 959 citations indexed

About

Adrian Woolfson is a scholar working on Molecular Biology, Genetics and Oncology. According to data from OpenAlex, Adrian Woolfson has authored 40 papers receiving a total of 959 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 11 papers in Genetics and 10 papers in Oncology. Recurrent topics in Adrian Woolfson's work include Chronic Lymphocytic Leukemia Research (7 papers), CAR-T cell therapy research (6 papers) and Monoclonal and Polyclonal Antibodies Research (5 papers). Adrian Woolfson is often cited by papers focused on Chronic Lymphocytic Leukemia Research (7 papers), CAR-T cell therapy research (6 papers) and Monoclonal and Polyclonal Antibodies Research (5 papers). Adrian Woolfson collaborates with scholars based in United States, United Kingdom and Australia. Adrian Woolfson's co-authors include César Milstein, Alan R. Fersht, Jean Chatellier, Jenny Carmichael, David C. Rubinsztein, M. Rothschild, Myriam M. Altamirano, Matthew V. Lorenzi, Irene Roberts and Anastasios Karadimitris and has published in prestigious journals such as Nature, Science and Proceedings of the National Academy of Sciences.

In The Last Decade

Adrian Woolfson

34 papers receiving 939 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Adrian Woolfson United States 15 394 281 185 124 98 40 959
Mathias Schmidt Germany 19 309 0.8× 167 0.6× 227 1.2× 53 0.4× 23 0.2× 68 1.0k
Srimoyee Ghosh United States 21 1.1k 2.7× 361 1.3× 286 1.5× 103 0.8× 82 0.8× 39 1.6k
Niklas Engels Germany 17 495 1.3× 688 2.4× 157 0.8× 41 0.3× 33 0.3× 29 1.3k
Valerie Stewart United States 12 745 1.9× 583 2.1× 342 1.8× 54 0.4× 48 0.5× 21 1.3k
Sigrid S. Skånland Norway 18 912 2.3× 522 1.9× 252 1.4× 37 0.3× 78 0.8× 51 1.5k
Vahe Bedian United States 16 539 1.4× 294 1.0× 258 1.4× 265 2.1× 131 1.3× 44 1.2k
Harry Gray United States 12 735 1.9× 120 0.4× 211 1.1× 55 0.4× 47 0.5× 37 1.1k
Dmitri Tentler Russia 18 1.1k 2.9× 106 0.4× 216 1.2× 90 0.7× 77 0.8× 29 1.5k
James W. Murphy United States 15 343 0.9× 592 2.1× 170 0.9× 312 2.5× 44 0.4× 24 1.3k
IJsbrand M. Kramer France 20 563 1.4× 215 0.8× 165 0.9× 55 0.4× 38 0.4× 33 1.0k

Countries citing papers authored by Adrian Woolfson

Since Specialization
Citations

This map shows the geographic impact of Adrian Woolfson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adrian Woolfson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adrian Woolfson more than expected).

Fields of papers citing papers by Adrian Woolfson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Adrian Woolfson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adrian Woolfson. The network helps show where Adrian Woolfson may publish in the future.

Co-authorship network of co-authors of Adrian Woolfson

This figure shows the co-authorship network connecting the top 25 collaborators of Adrian Woolfson. A scholar is included among the top collaborators of Adrian Woolfson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Adrian Woolfson. Adrian Woolfson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Woolfson, Adrian. (2023). Defining the Rules of Biology in the Age of Genome Writing. 2(6). 464–469.
3.
Wu, Andrew, et al.. (2023). The Hedgehog Pathway as a Therapeutic Target in Chronic Myeloid Leukemia. Pharmaceutics. 15(3). 958–958. 5 indexed citations
4.
Gopal, Ajay K., Ronald Levy, Roch Houot, et al.. (2020). First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20+ Non-Hodgkin Lymphomas. Clinical Cancer Research. 26(11). 2524–2534. 45 indexed citations
5.
Hughes, Derralynn, Özlem Göker-Alpan, Jaya Ganesh, et al.. (2020). A phase I/II multicenter gene therapy clinical study for Fabry disease. Molecular Genetics and Metabolism. 129(2). S77–S77. 4 indexed citations
6.
Li, Chen, Natalie A. Borg, Geoffrey I. Webb, et al.. (2018). Structural Capacitance in Protein Evolution and Human Diseases. Journal of Molecular Biology. 430(18). 3200–3217. 4 indexed citations
7.
Rothe, Katharina, et al.. (2017). SMO and GLI2 are key regulators mediating resistance of CML stem/progenitor cells to tyrosine kinase inhibitors. Experimental Hematology. 53. S62–S62. 2 indexed citations
8.
Gopal, Ajay K., Ronald Levy, Roch Houot, et al.. (2017). A PHASE I STUDY OF UTOMILUMAB (PF‐05082566), A 4‐1BB/CD137 AGONIST, IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH CD20+ NON‐HODGKIN'S LYMPHOMA. Hematological Oncology. 35(S2). 260–260. 8 indexed citations
9.
Gerds, Aaron T., Tetsuzo Tauchi, Ellen K. Ritchie, et al.. (2017). Phase I/II trial of glasdegib in patients with primary or secondary myelofibrosis.. Journal of Clinical Oncology. 35(15_suppl). 7061–7061. 2 indexed citations
10.
Gibb, Adam, Graham P. Collins, Rakesh Popat, et al.. (2017). BLOCKADE OF THE PD‐1 CHECKPOINT WITH ANTI–PD‐L1 ANTIBODY AVELUMAB IS SUFFICIENT FOR CLINICAL ACTIVITY IN RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA (CHL). Hematological Oncology. 35(S2). 67–67. 31 indexed citations
11.
Chen, Robert W., Stephen M. Ansell, Pier Luigi Zinzani, et al.. (2017). Phase 1b/3 study of avelumab-based combination regimens in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).. Journal of Clinical Oncology. 35(15_suppl). TPS7575–TPS7575. 3 indexed citations
12.
Lin, Hanyang, Adrian Woolfson, & Xiaoyan Jiang. (2016). New Mouse Models to Investigate the Efficacy of Drug Combinations in Human Chronic Myeloid Leukemia. Methods in molecular biology. 1465. 187–205. 2 indexed citations
13.
Woolfson, Adrian. (2015). Origins of life: An improbable journey. Nature. 520(7549). 617–618. 3 indexed citations
14.
Peng, Shaohua, Chad J. Creighton, Yiqun Zhang, et al.. (2013). Tumor grafts derived from patients with head and neck squamous carcinoma authentically maintain the molecular and histologic characteristics of human cancers. Journal of Translational Medicine. 11(1). 198–198. 55 indexed citations
15.
Barber, Nicole, et al.. (2009). Profiling CD antigens on leukaemias with an antibody microarray. FEBS Letters. 583(11). 1785–1791. 14 indexed citations
16.
Christopherson, Richard I., Nicole Barber, Larissa Belov, et al.. (2006). Classification of AML Using a Monoclonal Antibody Microarray. Humana Press eBooks. 125. 241–252. 10 indexed citations
17.
Altamirano, Myriam M., Adrian Woolfson, Alena Donda, et al.. (2001). Ligand-independent assembly of recombinant human CD1 by using oxidative refolding chromatography. Proceedings of the National Academy of Sciences. 98(6). 3288–3293. 37 indexed citations
18.
Woolfson, Adrian & César Milstein. (1994). Alternative splicing generates secretory isoforms of human CD1.. Proceedings of the National Academy of Sciences. 91(14). 6683–6687. 38 indexed citations
19.
Woolfson, Adrian. (1991). Conflict Talk: Sociolinguistic Investigations of Arguments in Conversations. Journal of Linguistic Anthropology. 1(1). 119–121. 62 indexed citations
20.
Woolfson, Adrian & M. Rothschild. (1990). Speculating about pyrazines. Proceedings of the Royal Society B Biological Sciences. 242(1304). 113–119. 55 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mathias Schmidt Breakdown of academic impact, for papers by Srimoyee Ghosh Breakdown of academic impact, for papers by Niklas Engels Breakdown of academic impact, for papers by Valerie Stewart Breakdown of academic impact, for papers by Sigrid S. Skånland Breakdown of academic impact, for papers by Vahe Bedian Breakdown of academic impact, for papers by Harry Gray Breakdown of academic impact, for papers by Dmitri Tentler Breakdown of academic impact, for papers by James W. Murphy Breakdown of academic impact, for papers by IJsbrand M. Kramer
Rankless by CCL
2026